MONITORING OF ANTICOAGULANT THERAPY IN HEART DISEASE: CONSIDERATIONS FOR THE CURRENT ASSAYS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

BOROUMAND M.A.; GOUDARZINEZHAD H.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER Year:2010 | Volume:5 | Issue:2 Page(s): 57-68

Download Full-Text

View:

338

Download:

195

Cites:

Information Journal Paper

Title

MONITORING OF ANTICOAGULANT THERAPY IN HEART DISEASE: CONSIDERATIONS FOR THE CURRENT ASSAYS

Author(s)

BOROUMAND M.A. | GOUDARZINEZHAD H.R. | Issue Writer Certificate

Keywords

ANTICOAGULANTS

HEART

INTERNATIONAL NORMALIZED RATIO

PARTIAL THROMBOPLASTIN

PROTHROMBIN TIME

Abstract

Clinicians should be aware of new developments to familiarize themselves with pharmacokinetic and pharmacodynamic characteristics of new anticoagulant agents to appropriately and safely use them. For the moment, cardiologists and other clinicians also require to master currently available drugs, realizing the mechanism of action, side effects, and laboratory monitoring to measure their anticoagulant effects. Warfarin and heparin have narrow therapeutic window with high inter- and intra-patient variability, thereby the use of either drug needs careful laboratory monitoring and dose adjustment to ensure proper antithrombotic protection while minimizing the bleeding risk. The PROTHROMBIN TIME (PT) and the activated PARTIAL THROMBOPLASTIN time (aPTT) are laboratory tests commonly used to monitor warfarin and heparin, respectively. These two tests depend highly on the combination of reagent and instrument utilized. Results for a single specimen tested in different laboratories are variable; this is mostly attributable to the specific reagents and to a much lesser degree to the instrument used. The PT stands alone as the single coagulation test that has undergone the most extensive attempt at assay standardization. The INTERNATIONAL NORMALIZED RATIO (INR) was introduced to ‘‘normalize’’ all PT reagents to a World Health Organization (WHO) reference thromboplastin preparation standard, such that a PT measured anywhere in the world would result in an INR value similar to that which would have been achieved had the WHO reference thromboplastin been utilized. However, INRs are reproducible between laboratories for only those patients who are stably anticoagulated with vitamin K antagonists (VKAs) (i.e., at least 6 weeks of VKA therapy), and are not reliable or reproducible between laboratories for patients for whom VKA therapy has recently been started or any other clinical conditions associated with a prolonged PT such as liver disease, disseminated intravascular coagulation, and congenital factor deficiencies. In contrast to marked progress in the standardization of PT reagents for INR reporting, no standardization system has been globally adopted for standardization of PTT reagents. Recently College of American Pathologists recommend that individual laboratories establish their own therapeutic range by using aPTT values calibrated against accepted therapeutic unfractionated heparin (UFH) levels calibrated against accepted therapeutic UFH levels performing anti-Xa test (which is the most accurate assay for monitoring UFH therapy).Herein, we review recent data on the monitoring of conventional anticoagulant agents. Marked interlaboratory variability still exists for PT, INR, and PTT tests. Further research should be focused on improving the standardization and calibration of these assays.

Cites

No record.

References

Cite

APA: Copy

BOROUMAND, M.A., & GOUDARZINEZHAD, H.R.. (2010). MONITORING OF ANTICOAGULANT THERAPY IN HEART DISEASE: CONSIDERATIONS FOR THE CURRENT ASSAYS. THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER, 5(2), 57-68. SID. https://sid.ir/paper/301962/en

Vancouver: Copy

BOROUMAND M.A., GOUDARZINEZHAD H.R.. MONITORING OF ANTICOAGULANT THERAPY IN HEART DISEASE: CONSIDERATIONS FOR THE CURRENT ASSAYS. THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER[Internet]. 2010;5(2):57-68. Available from: https://sid.ir/paper/301962/en

IEEE: Copy

M.A. BOROUMAND, and H.R. GOUDARZINEZHAD, “MONITORING OF ANTICOAGULANT THERAPY IN HEART DISEASE: CONSIDERATIONS FOR THE CURRENT ASSAYS,” THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER, vol. 5, no. 2, pp. 57–68, 2010, [Online]. Available: https://sid.ir/paper/301962/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops